Novavax to Present Phase I/IIa Trial Data Results in an Investor Conference Call on August 26, 2008
ROCKVILLE, Md., August 21, 2008 /PRNewswire-FirstCall/ -- Novavax, Inc. today announced that the Company will hold an investor conference call to discuss results from the Phase I/IIa human clinical trial of Novavax's H5N1 pandemic influenza VLP vaccine candidate at 11:00 a.m. Eastern Time on August 26, 2008.
The call will be hosted by Novavax President and Chief Executive Officer Dr. Rahul Singhvi and other members of senior management, including Chief Medical Officer, Dr. Penny Heaton. A question and answer session will follow the presentation of the data. The dial-in number for the conference call is USA and Canada (866) 244 4515, International: (703) 639 1168.
A live audio webcast of the conference call will be available at www.novavax.com. Please connect to this website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be needed to hear the webcast. A replay of the webcast will be available for 90 days after the webcast and a replay of the conference call will also be available by telephone beginning 1pm EDT, August 26, 2008 through midnight September 2, 2008. To access the replay, dial (703) 925 2533 and enter pass code 1272626.
About Novavax, Inc.
Novavax, Inc. is a clinical stage biotechnology company, creating novel vaccines to address a broad range of infectious diseases worldwide using advanced proprietary virus-like particle (VLP) technology. The Company produces these VLP based, potent, recombinant vaccines utilizing new, and efficient manufacturing approaches. Additional information about Novavax is available at www.novavax.com and in the Company's various filings with the Securities and Exchange Commission.
Forward Looking Statements
Statements herein relating to future development results and performance, conditions or strategies and other matters, including expectations regarding product and clinical developments are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Novavax cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including risks relating to the early stage of Novavax's product candidates under development; current results may not be predictive of future pandemic results, results of our seasonal influenza vaccine or any other vaccine that we may develop; further testing is required before FDA can be applied for and the FDA may not approve the pandemic vaccine even if further trial results are similar to those disclosed herein; uncertainties relating to clinical trials; dependence on the efforts of third parties; competition for clinical resources and patient enrollment from drug candidates in development by other companies with greater resources and visibility; and risks that we may lack the financial resources and access to capital to fund our operations including further clinical trials. Further information on the factors and risks that could affect Novavax's business, financial conditions and results of operations, is contained in Novavax's filings with the U.S. Securities and Exchange Commission, which are available at http://www.sec.gov. These forward-looking statements speak only as of the date of this press release, and Novavax assumes no duty to update forward-looking statements.
CONTACT: Tricia Richardson of Novavax, Inc., +1-240-268-2031
Web site: http://www.novavax.com/
Ticker Symbol: (NASDAQ-NMS:NVAX)
Terms and conditions of use apply
Copyright © 2008 PR Newswire Association LLC. All rights reserved.
A United Business Media Company
Posted: August 2008